glp-1 agonists reduce inflammation The anti-inflammatory feature of glucagon-like peptide-1 and its based diabetes drugs—Therapeutic potential exploration in lung injury Taming the fires

The review also discusses emerging data in peripheral artery disease (e.g., STRIDE trial)

27 Importantly, GLP-1 action is short-lived, with a half-life of just 12 minutes in the bloodstream under normal physiological conditions, after which it is broken down by the enzyme dipeptidyl peptidase IV (DPP-4), resulting in a loss of its biological activity

They were found to have significant HbA1c, and weight reduction compared to placebo in patients with diabetes and obesity respectively

With the proper screenplay, their weight loss journey could be worthy of a Best Picture nomination

Likely, multiple mechanisms contribute

Research, including recent findings from the SELECT trial, indicates that GLP-1 agonists like semaglutide can significantly reduce the risk of major cardiovascular events, such as heart attacks and strokes, especially in individuals with obesity but without diabetes